The gene for autosomal recessive spinal muscular atrophy (SMA) has been mapped to 5q12 in a region that contains repeated markers and genes. Three cDNAs that detect deletions in SMA patients have been reported. One of these, the survival motor neuron (SMN) cDNA, is encoded by two genes (SMN T and SMN C ) which are distinguished by base changes in exons 7 and 8. Exon 7 of the SMN T gene is not detectable in ∼95% of SMA cases, due either to deletion or sequence conversion. There is limited information on the mutations in SMA patients that have detectable SMN T : these are critical for confirmation of SMN T as the SMA gene. Using SSCP analysis of the SMN exons we screened our SMA patients that possess at least one intact SMN T allele for mutations in SMN T . We identified one type I SMA patient with an 11 bp duplication in exon 6 which causes a frameshift and premature termination of the deduced SMN T protein. Dosage and SSCP analysis of SMN T in this family indicated that the father contributed a SMN T -deleted allele to the affected child whereas the mother passed on the 11 bp exon 6 duplication SMN T allele. Analysis of RNA by RT-PCR conclusively demonstrated that the 11 bp duplication is associated with the SMN T locus and not SMN C . This mutation provides strong support for SMN as the SMA-determining gene and indicates that disruption of SMN T on its own is sufficient to produce a severe type I SMA phenotype.
INTRODUCTION
Proximal spinal muscular atrophy (SMA) is characterized by degeneration of α-motor neurons in the anterior horn of the spinal cord. SMA has an estimated incidence of 1 in 10 000 live births, with a carrier frequency of ∼1 in 40 individuals (1) . Childhood onset SMA is classified into three groups on the basis of age of onset and clinical course (2) . Type I SMA (Werdnig-Hoffmann disease) is the most severe form, with clinical onset before the age of six months and death generally occurring within the first two years. Type II SMA is of intermediate severity: onset occurs before 18 months of age, and patients never gain the ability to walk. Type III SMA (Kugelberg-Welander disease) is the mildest form, with onset after 18 months and patients able to both stand and walk on their own.
All three forms of childhood SMA have been mapped to chromosome 5q11.2-q13.3 by linkage analysis (3) (4) (5) (6) (7) (8) (9) (10) (11) . A number of physical maps of this area have been produced, but no consensus map has been achieved due to the complex genomic organization of the region (12) (13) (14) (15) (16) (17) (18) , which contains numerous repeated sequences, including polymorphic markers and genes (15) (16) (17) (18) (19) (20) . Some of these multicopy markers were used to further refine the position of the SMA gene by the demonstration of linkage disequilibrium (15, (19) (20) (21) . Analysis of these markers showed specific alleles associated with SMA, loss of a copy of the marker in severe SMA chromosomes, and deletion of all copies of marker alleles on some SMA chromosomes (20) (21) (22) .
Three cDNAs that identify deletions in the SMA region have been reported: the survival motor neuron (SMN) gene (18) ; the neuronal apoptosis inhibitory protein (NAIP) gene (16) ; and the XS2G3 cDNA (17) . The NAIP and XS2G3 cDNAs detect the same deletion in ∼50% of type I SMA patients and a smaller proportion of type II and III individuals; they also rarely detect deletions in carrier parents with no obvious clinical symptoms (16, 17, 22) .
The third cDNA, survival motor neuron (SMN), is encoded by two nearly-identical genes: centromeric SMN (SMN C ) and telomeric SMN (SMN T ). SMN C and SMN T are both transcribed, and can be distinguished by two single nucleotide sequence variations in exons 7 and 8, neither of which alter the coding sequence (18) . Absence of SMN T exon 7 has been reported in *To whom correspondence should be addressed at: Department of Neurology, 452 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA ∼95% of SMA patients, due either to conversion of SMN T to SMN C or deletion of SMN T (18, (23) (24) (25) . The presence of large deletions in a homozygous state is strongly correlated with the severe SMA phenotype (22) . Conversion can be demonstrated in patients who have exon 8 of SMN T but lack detectable exon 7 of SMN T (18, 25) : in our studies these conversion events predominate in mild patients (25) . In individuals that do not retain SMN T exon 8, conversion can be implicated on one chromosome of mild patients from both dosage (24) and marker studies (20, 22) . This would indicate that conversion (as opposed to deletion) is a common mutation on mild chromosomes. A limited number of small mutations in SMN T have been reported, including a 4 bp deletion in exon 3 (18, 23) . In order to confirm SMN as the SMA gene and determine whether mutations in SMN T are solely responsible for the SMA phenotype, it is extremely important to identify additional small mutations in this gene.
In the present study, we have used SSCP analysis to screen the SMN gene for mutations in our population of SMA-like individuals who retain at least one copy of SMN T . We have identified a type I spinal muscular atrophy patient who possesses one SMN T allele containing an 11 bp duplication in exon 6 and one SMN T -deleted allele. RNA studies clearly indicate that the 11 bp duplication affects the SMN T locus and not SMN C . This finding strongly supports SMN T as the SMA-determining gene, and indicates that mutations which disrupt production of full length protein from the SMN T locus can be solely responsible for producing a severe type I SMA phenotype.
RESULTS
Single strand conformation polymorphism (SSCP) analysis of SMN exons in the type I SMA patient #367 demonstrated an abnormal exon 6 SSCP pattern (Fig. 1A) . A previously reported PCR-based assay was used to confirm that the patient retained at least one copy of SMN T exons 7 and 8 (26) ; PCR amplification also demonstrated that exon 5 of NAIP was present (16) . Sequence analysis of patient #367 exon 6 subclones revealed an 11 bp duplication of nucleotides 801-811 (TGC TGA TGC TT) of the SMN gene ( Fig. 2A and B) . The duplication results in a frameshift and a premature termination codon 15 nucleotides downstream, predicting a SMN protein product containing seven altered amino acids prior to truncation. The duplication was absent in 100 unrelated healthy individuals (200 chromosomes) as well as in 60 non-SMN T deleted individuals who had been evaluated in our laboratory for a possible diagnosis of SMA (120 chromosomes).
In order to determine whether the mutated exon 6 is contained within the telomeric or centromeric copy of SMN, RT-PCR amplification of skeletal muscle RNA was conducted using a [γ-32 P]dATP end-labelled forward primer within exon 6 and a reverse primer within exon 8. The amplified region contains the two reported coding region sequence differences between SMN T and SMN C in exons 7 and 8. The exon 8 sequence change (nucleotide 1155; g, telomeric; a, centromeric) produces a DdeI site in the centromeric copy only, allowing SMN T and SMN C to be distinguished using a restriction digest assay (Fig. 3) . RT-PCR amplification of patient RNA produced the expected 503 and 449 bp products [the smaller product due to removal of exon 7 in alternatively-spliced SMN C transcripts (18)], as well as an abnormal larger product consistent with an SMN allele containing the 11 bp duplication. After DdeI digestion, the 503 bp product was completely cut, indicating that no normally-sized SMN T was present in the patient. The larger abnormal product was not digested, demonstrating that the 11 bp duplication is within SMN T , not SMN C . These results are consistent with the patient being a compound heterozygote: one SMN T allele has been deleted, while the other allele contains the 11 bp duplication. This restriction enzyme assay also provides some insight into the splicing pattern of the SMN loci. In the normal control, qualitative examination indicates that ∼70% of the SMN transcripts contain exon 7, while 30% do not. It can also be seen that in this patient the SMN T locus only produces transcripts containing exon 7, since no abnormal 460 bp band is present. Sequence analysis of patient subclones containing the mutant allele demonstrated the nucleotide sequence specific to SMN T exons 7 and 8, confirming that the mutated transcripts were derived from SMN T .
In order to investigate the segregation of the SMN T alleles within this family, SSCP and dosage analysis were performed. SSCP analysis of exon 6 in the parents of the proband revealed an abnormal pattern in the mother and a normal pattern in the father (Fig. 1A) . The maternal mutant exon 6 allele was subcloned and sequenced, confirming that the mother possesses a SMN T allele containing the 11 bp duplication. Dosage studies of SMN T and SMN C were also performed (Fig. 1B) . While a normal dosage DdeI restriction digest assay of SMN exon 6-8 RT-PCR amplification products. DdeI cuts SMN C but not SMN T , allowing the two copies of the gene to be distinguished. The normal full-length amplified fragment has a size of 503 bp. In the patient (P), an additional larger band which does not cut with DdeI is present (*). This demonstrates that the 11 bp duplication is present in SMN T , not SMN C . The 503 bp fragment is completely digested by DdeI in the patient, indicating that no normally-sized SMN T is present. Exon 7 may be spliced out of SMN C transcripts: the 449 bp fragment represents this alternatively-spliced message. In the normal control (C), it appears from qualitative analysis that ∼70% of the SMN transcripts contain exon 7, while 30% do not. It can be seen that the SMN T locus only produces transcripts containing exon 7, since no abnormal 460 bp band is present in the patient. C, control; P, patient; SMN∆, individual lacking both SMN T alleles.
pattern consistent with the presence of two SMN T alleles was observed in the mother, an SMN T band of decreased intensity was seen in both the father and proband, suggesting that they each have an SMN T deletion on one chromosome. These results again support the presence of two different SMN T mutations in the affected individual: the patient received an SMN T -deleted chromosome from his father, and an SMN T allele containing an 11 bp duplication in exon 6 from his mother.
DISCUSSION
The SMA gene is located in a region that contains many repeated sequences, including genes and markers (15) (16) (17) (18) (19) (20) . Three cDNA clones from the SMA region detect deletions in SMA patients (16) (17) (18) . The cDNAs for NAIP and XS2G3 detect the same deletion in ∼50% of type I patients (16, 17) . However, these cDNAs are also deleted in asymptomatic carriers of SMA (16, 17, 24, (27) (28) (29) . The third cDNA, SMN, is encoded by two genes that exist in almost identical copies (SMN T and SMN C ) which are only distinguishable by single base pair changes in exons 7 and 8 (18) . In ∼95% of SMA patients exon 7 of the SMN T gene is not detectable, which is usually assumed to be due to deletion of the SMN T gene (18, 24, (27) (28) (29) . However, analysis of patients who have no detectable SMN T exon 7 but do possess SMN T exon 8 indicates that conversion of SMN T to SMN C occurs (as opposed to deletion) in these cases (25) . Therefore, the absence of SMN T can be due either to deletion or conversion of
Association studies with the marker AgI-CA revealed a clear correlation with phenotype: one copy of the marker on both chromosomes (or a 1,1 genotype) occurs more frequently in type I SMA, whereas a 1,2 genotype is more frequent in type II SMA (20, 22) . In addition, we have shown that a 1,1 genotype of AgI-CA correlates with type I SMA chromosomes that have a deletion of NAIP, indicating that large homozygous deletions are correlated with type I SMA (22) . These results would also indicate that type II SMA patients have one chromosome which has a large deletion (single copy of AgI-CA) and one chromosome which does not (two copies of AgI-CA); this could either be due to a small deletion or conversion of SMN T to SMN C . Analysis of patients who retain exon 8 of SMN T but not exon 7 clearly indicates that conversion does occur in the SMA locus (18, 25) ; in our studies this mutation predominates on mild chromosomes (25) . In cases where SMN T exon 8 is not present, it is more difficult to distinguish deletion from conversion events. However, initial dosage studies using the ratio of SMN C to SMN T strongly imply that a large number of type II and III chromosomes do possess conversion alleles as opposed to deletions (24) . We would suggest that the simplest explanation for these findings is that severe SMA is caused by the inability of the SMN T locus to produce a critical isoform (two null alleles for the critical isoform), whereas milder SMA (type II and III) results from a severe null allele for the critical isoform in combination with a mild allele. It would apppear likely that sequence converted alleles predominate in types II and III SMA (24, 25) . Sequence converted alleles could also occur in severe SMA; however, in this case the SMN T gene would still be nonfunctional due either to the introduction of additional mutations into the SMN T gene or an effect on its expression. In this report we show by RNA studies that in the type I patient with an 11 bp duplication in exon 6 of SMN T there is no RNA capable of producing a full length SMN protein from the SMN T locus, which is consistent with the hypothesis that type I SMA is caused by null mutation of a critical isoform from the SMN T gene. Direct proof of the hypothesis that a critical isoform of SMN T is lacking in the motor neurons of type I SMA patients must await further studies, particularly at the protein level.
Apart from sequence conversion and deletion, there is extremely limited information regarding other SMA-causing mutations. In this paper we have analyzed our patients who do not lack SMN T for mutations in SMN T . Lefebvre et al. have reported a missense mutation in exon 6 and two short deletions in the consensus splice sites of introns 6 and 7 that are assumed to cause SMA since they are not observed in normal controls (18) . However, the most conclusive mutation to date in implicating SMN T as the true SMA-determining gene is a 4 bp deletion in exon 3 (23) . This deletion was originally identified in a type II consanguineous family, but has also been shown to occur in one type I and two type III SMA patients. This mutation would be predicted to disrupt the reading frame of the SMN T gene and produce a severe phenotype; however, it results in all three SMA phenotypes. If we assume that the other allele in the type I patient is null for the critical isoform and in the type III patient is partially functional, then the situation for the 4 bp deletion allele is similar to that reported for cystic fibrosis (CF): the missense R117H mutation is observed in three phenotypic variants of CF, with the severity of the phenotype modulated by intron variants that affect splicing efficiency (30) . Therefore in the type I patient, exon 3 containing the 4 bp allele would not be skipped efficiently, resulting in two null alleles for the critical isoform, whereas in the milder type II consanguineous patient, sufficient skipping occurs to produce some product.
It is extremely important to identify additional mutations that would clearly indicate that SMN T is the SMA gene. To date no duplication mutations have been reported in SMA, although they may be predicted to occur due to the repetitive nature of this region. In this paper we show that an 11 bp duplication occurs in exon 6 of the SMN T gene and causes type I SMA. The demonstration of duplication in SMA indicates that this type of mutation does occur. It is also likely that whole exon duplications occur in the SMN T gene; however, these would not be detected by our SSCP screening assay. Interestingly, whole exon mutations would not be predicted to disrupt translational reading frame and therefore could give rise to a mild phenotype. The frequency of homozygous absence of SMN T in type III patients seems to be slightly lower than in types I and II SMA (27) . It is possible that this slightly lower frequency of detectable SMN alteration in type III SMA might be accounted for by whole exon duplications being type III SMA alleles.
Dosage analysis of SMN T exon 7 in our population of potential SMA patients that retain at least one copy of exon 7 SMN T indicates that four patients (and only one type I patient) are due to mutations at the 5q12 locus. That single type I SMA patient has an 11 bp duplication in exon 6 of the SMN T gene, which clearly disrupts the reading frame of SMN T and would appear to indicate that mutations which disrupt SMN T can cause severe SMA. This would be consistent with the hypothesis that mutations in SMN T are solely responsible for SMA: a null for critical isoform or truncated SMN T allele in the homozygous state gives rise to severe SMA without the need for deletion of additional genes. This patient does not lack exon 5 of the NAIP gene, yet has a severe SMA phenotype. We cannot rule out the possibility that this 11 bp duplication allele could be found in a patient with a milder SMA phenotype: we have only identified the mutation in a type I SMA patient. Mild (type II or III) SMA may be caused by one chromosome containing a partially functional allele. These mild alleles can probably be modified by genetic background or modifier genes, thus explaining the exceptional type II/III families where an apparently normal sibling has absence of SMN T (27) (28) (31) (32) .
In conclusion, we have shown that an 11 bp duplication which disrupts SMN T is a type I SMA allele. This would indicate that mutations in SMN T are solely responsible for SMA, and that it is likely that null mutations for a critical isoform produced by the SMN T locus give rise to severe SMA. Confirmation of the lack of a critical isoform in motor neurons from the SMN T locus must await further studies at the protein level.
MATERIALS AND METHODS

Patient selection/diagnosis of SMA
The patients selected for this study were from two groups: families that were collected for genetic studies (whom we have described previously) and patients sent to our laboratory for diagnostic purposes. The first group of patients fulfilled the criteria for SMA defined by the international SMA consortium (2) . Patient #367 is from this first group of patients and has the classical features of type I SMA: confirmatory EMG and muscle pathology, with death at the age of 6 months. Sixty patients that had at least one copy of exon 7 of the SMN T gene were analysed for SMN alterations in exons other than exon 7. However, dosage assays for SMN T exon 7 are only consistent with four of these patients being SMA caused by mutations at the 5q12 locus (most of these SMA patients would be expected to be compound heterozygotes).
DNA procedures
SSCP analysis. SSCP analysis was performed according to the procedure of Orita et al. (33) with minor modifications. PCR primers used for amplification of SMN T exons were based on intron/exon boundary DNA sequences reported by Burglen et al. (34) . The sequences of PCR primers 541C618 (5′-CTC CCA TAT GTC CAG ATT CTC TTG-3′) and EX63 (5′-AAG AGT AAT TTA AGC CTC AGA CAG-3′) used for amplification of SMN exon 6 were kindly provided by Dr Judith Melki (Hopital des Enfants Malades, Paris, France). DNA from peripheral blood leukocytes (100 ng) was amplified by PCR in a 25 µl reaction mixture containing 200 µM dNTPs, 1 U Taq polymerase (Perkin Elmer), 30 ng of each primer, 2.5 mM MgCl 2 , 2.5 µl 10× PCR buffer (670 mM Tris, 100 mM β-mercaptoethanol, 166 mM ammonium sulfate, 67 µM EDTA, 0.5 µg/ml BSA), and 0.1 µl [α-32 P]ATP (10 µCi/µl; Amersham). The PCR reaction consisted of an initial denaturation step at 94_C for 2 min followed by 35 cycles of 30 s at 94_C, 30 s at 58_C and 30 s at 72_C. There was no final extension step. Four µl of PCR product was added to an equal volume of loading dye (95% formamide, 10 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol). The samples were denatured at 95_C for at least 5 min and placed on ice until loading on a 0.5× MDE gel (AT Biochem). The gels were run at 6 W for 15 h at 4_C, then transferred onto blotting paper (Alhstrom), dried and exposed to Hyperfilm-MP (Amersham) for 12-24 h at -70_C.
PCR amplification of SMN. DNA was extracted from peripheral blood and skeletal muscle using a salting out protocol (35) . SMN exon 6 was PCR amplified using 30 ng each of primers 541C618 and EX63 (as for SSCP analysis of exon 6) in a PCR reaction mixture of 50 µl containing 1 U Taq polymerase (Perkin Elmer), 0.5 mM dNTPs, 3 mM MgCl 2 and 5 µl 10× PCR buffer. The PCR reaction consisted of an initial denaturation step at 95_C for 5 min followed by 35 cycles of 1 min at 95_C, 2 min at 55_C and 3 min at 72_C. A final extension of 8 min at 72_C was performed. The PCR products were visualized on ethidium bromide-stained 8% polyacrylamide gels: the mutant exon 6 allele migrated more slowly than the smaller normal allele, allowing the two to be easily distinguished (a heteroduplex band was also seen on the gel when the mutant allele was present). The presence of SMN T exons 7 and 8 was confirmed using a previously-described protocol (26) .
PCR amplification of NAIP. PCR amplification of NAIP exon 5 was performed using primers described by Roy et al. (16) . Reactions were carried out in 2.5 mM MgCl 2 buffer, with an initial denaturation step of 3 min at 94_C, followed by 35 cycles of 94_C for 30 s, 58_C for 30 s and 72_C for 30 s. There was no final extension step. The PCR products were visualized on ethidium bromide-stained 2% agarose gels and scored for the presence or absence of exon 5.
Dosage analysis of SMN T and SMN C . PCR amplification of SMN exon 7 was performed using primers R111 and X7-DraI described by Lefebvre et al. (18) and van der Steege et al. (26) . PCR amplification of CFTR exon 4 was performed using primers CF621-F and CF621-R (36). R111 and CF621-F primers were end-labelled with [γ-32 P]ATP (10 µCi/µl; Amersham). DNA from peripheral blood leukocytes (200 ng) was amplified by PCR in a 25 µl reaction mixture containing 200 µM dNTPs, 0.5 U Taq polymerase (United States Biochemicals), 30 ng of each primer, 3 mM MgCl 2 and 2.5 µl 10× PCR buffer (United States Biochemicals). The PCR reaction consisted of an initial denaturation step at 95_C for 5 min followed by 16 cycles of 1 min at 95_C, 2 min at 55_C and 3 min at 72_C. Eight µl of PCR product were digested overnight at 37_C using 20 U DraI (New England Biolabs) and 1 µl of the buffer supplied by the manufacturer. The digestion products were combined with 5 µl loading dye and electrophoresed on a 6% denaturing polyacrylamide gel. The gel was dried and exposed to Hyperfilm-MP (Amersham) for 16 h.
RNA procedures
RT-PCR. Total RNA was isolated from ∼200 mg of skeletal muscle using TRIzol Reagent (Gibco BRL), then first-strand cDNA synthesis was carried out from 2 µg RNA with oligo(dT) and Superscript II Rnase H -Reverse Transcriptase (200 U/µl; Gibco BRL), according to the manufacturer's instructions. The single-stranded cDNAs were PCR amplified using 30 ng each of forward primer (541C618) within exon 6 and reverse primer (541C1120; 5′-CTA CAA CAC CCT TCT CAC AG-3′) within exon 8, with reaction mixture components and PCR conditions identical to those used for PCR amplification of SMN exon 6 (as above).
Restriction enzyme analysis. PCR amplification of SMN exons 6-8 from single-stranded cDNA was performed as above, using 30 ng of forward primer (541C618) end-labelled with [γ-32 P]ATP (10 µCi/µl; Amersham). Eight µl of PCR product was digested overnight at 37_C with 10 U DdeI (New England Biolabs) and 1 µl of the buffer supplied by the manufacturer. The digestion products were combined with 5 µl loading dye, and 3 µl of the mixture was electrophoresed on a 5% denaturing polyacrylamide gel. For reference, 3 µl of undigested PCR product was also electrophoresed on the same gel. The gels were run for 12 000 V-h, then transferred onto blotting paper (Alhstrom), dried and exposed to Hyperfilm-MP (Amersham) for 3-6 h at room temperature.
Subcloning and sequencing
PCR and RT-PCR amplification products to be sequenced were subcloned into the TA cloning vector (Invitrogen), according to the manufacturer's instructions. Sequencing of miniprep DNA that had been purified from the subclones using Wizard Minipreps (Promega) was performed with the dsDNA Cycle Sequencing System (Gibco BRL). Sequencing reaction products were analyzed using a 5% denaturing polyacrylamide gel. The gels were transferred onto blotting paper, dried and exposed to Hyperfilm-MP (Amersham) for 12-24 h at -70_C. The mutation was sequenced on both DNA strands, and multiple subclones were analyzed.
